Hims & Hers Health, Inc. $HIMS Stake Lifted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

Key Points

• MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Hims & Hers Health by 3.4% during the first quarter, owning approximately $6.25 million worth of stock.
• Wall Street analysts have recently downgraded their ratings on Hims & Hers Health, with Truist Financial lowering their price target from $48.00 to $37.00 and maintaining a "hold" rating.
• Insider selling has been significant, with CEO Andrew Dudum selling 660,000 shares for a total of approximately $33.4 million, representing a 22.96% decrease in his ownership.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 3.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 211,480 shares of the company's stock after acquiring an additional 6,876 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.09% of Hims & Hers Health worth $6,249,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Bosun Asset Management LLC bought a new position in shares of Hims & Hers Health in the first quarter worth about $272,000. Alliancebernstein L.P. boosted its stake in shares of Hims & Hers Health by 10.7% in the first quarter. Alliancebernstein L.P. now owns 812,123 shares of the company's stock worth $23,998,000 after acquiring an additional 78,756 shares during the period. Metavasi Capital LP boosted its stake in shares of Hims & Hers Health by 3.5% in the first quarter. Metavasi Capital LP now owns 193,968 shares of the company's stock worth $5,732,000 after acquiring an additional 6,545 shares during the period. Nomura Holdings Inc. boosted its stake in shares of Hims & Hers Health by 433.2% in the first quarter. Nomura Holdings Inc. now owns 64,055 shares of the company's stock worth $1,893,000 after acquiring an additional 52,042 shares during the period. Finally, DRW Securities LLC boosted its stake in shares of Hims & Hers Health by 182.2% in the first quarter. DRW Securities LLC now owns 17,343 shares of the company's stock worth $512,000 after acquiring an additional 38,443 shares during the period. Institutional investors own 63.52% of the company's stock.

Insider Buying and Selling

In other news, CFO Oluyemi Okupe sold 23,107 shares of the company's stock in a transaction on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the sale, the chief financial officer owned 63,222 shares of the company's stock, valued at approximately $2,987,239.50. This represents a 26.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael Chi sold 17,102 shares of the stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the completion of the transaction, the insider owned 278,654 shares in the company, valued at $16,649,576.50. This represents a 5.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,384,728 shares of company stock valued at $71,149,098. 17.71% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Truist Financial decreased their target price on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research report on Monday, August 18th. UBS Group set a $30.00 target price on Hims & Hers Health in a research report on Monday, June 23rd. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Finally, Wall Street Zen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Two equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has an average rating of "Reduce" and an average price target of $38.92.

Hims & Hers Health Trading Up 7.2%

NYSE:HIMS traded up $3.72 during midday trading on Friday, hitting $55.48. The stock had a trading volume of 35,408,839 shares, compared to its average volume of 24,765,500. Hims & Hers Health, Inc. has a one year low of $15.73 and a one year high of $72.98. The company has a market capitalization of $12.54 billion, a price-to-earnings ratio of 69.35, a PEG ratio of 3.75 and a beta of 2.14. The stock has a 50-day moving average of $50.26 and a 200 day moving average of $45.30. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business's revenue for the quarter was up 72.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.